Sarepta Therapeutics (SRPT) Capital Expenditures (2010 - 2026)

Sarepta Therapeutics has reported Capital Expenditures for 17 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 95.23% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $60.4 million (down 59.23% YoY), and the FY2025 full-year result was $102.0 million, down 25.54% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.1 million, down from $3.6 million in the prior quarter.
• The five-year high for Capital Expenditures was $43.7 million in Q1 2025, with the low at $2.1 million in Q1 2026.
• Average Capital Expenditures over 5 years is $20.5 million, with a median of $19.0 million recorded in 2023.
• Year-over-year, Capital Expenditures surged 261.02% in 2022 and tumbled 95.23% in 2026.
• Tracing SRPT's Capital Expenditures over 5 years: stood at $8.0 million in 2022, then surged by 139.06% to $19.0 million in 2023, then surged by 100.02% to $38.1 million in 2024, then tumbled by 90.57% to $3.6 million in 2025, then slumped by 42.05% to $2.1 million in 2026.
• The last three Capital Expenditures figures came in at $2.1 million (Q1 2026), $3.6 million (Q4 2025), and $22.9 million (Q3 2025), per Business Quant data.

Peer Comparison